Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NovAliX Enters into Alliance with Kyowa Hakko Kirin

Published: Monday, January 14, 2013
Last Updated: Monday, January 14, 2013
Bookmark and Share
Companies will collaborate to develop novel drug candidates against protein-protein interaction targets.

NovAliX SAS has announced that it has entered into a fragment-based drug discovery alliance with Kyowa Hakko Kirin Co., Ltd., Japan.

Within the alliance, the companies will collaborate to develop novel drug candidates against protein-protein interaction targets.

NovAliX will generate novel lead candidates using the broad spectrum of its biophysical capabilities and its medicinal chemistry expertise.

Under the terms of the agreement NovAliX will receive technology access fees as well as further research funding payments and milestones.

Stephan Jenn, President of NovAliX, stated, "For NovAliX this drug discovery alliance represents a significant development of our established relation with Kyowa Hakko Kirin. This drug discovery collaboration with a leading Japanese pharmaceutical company also confirms the quality of our discovery platforms and its ability to deliver valuable lead candidates."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

NovAliX and Inventiva Form a Strategic Alliance on Nuclear Receptors
Inventiva and NovAliX announced that they have entered into a strategic alliance dedicated to the discovery of clinical candidates, targeting nuclear receptors.
Tuesday, April 09, 2013
NovAliX Enters into Multi-Target Integrated Drug Discovery Collaboration with Teijin Pharma
The companies will develop novel drug candidates against multiple targets across different therapeutic areas.
Thursday, January 12, 2012
NovAliX to Collaborate with the Fondation Jérôme Lejeune on Down Syndrome (Trisomy 21)
NovAliX will use its expertise and capabilities in medicinal chemistry and structural biology to develop small molecule lead candidates targeting the CBS.
Friday, September 16, 2011
NovAliX and Galapagos Collaborate in Osteoarthritis Discovery Research Program
NovAliX will be responsible for the discovery of specific small molecule lead candidates for a novel, validated osteoarthritis target chosen by Galapagos.
Monday, August 29, 2011
Scientific News
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
Resurrecting an Abandoned Drug
Previously discarded drug shows promise in helping human cells in a lab dish fight off two different viruses.
Safer, Cheaper, Greener and More Efficient System for Organic Synthesis
The new medium not only supports organic synthesis it also produces considerably higher yields of product than pure organic solvents.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Collaboration to Develop Cancer Therapeutics
Major license agreement with Merck, enabled by Blavatnik Biomedical Accelerator, aims to develop therapy for most common form of acute leukemia.
Faster UVA Molecular Analysis Technology
There are people in the world – chemical engineers, astronomers, national defense scientists investigating an explosion – who need to know just what something is made of, down to the molecular level.
Scientists Synthesize Anti-Cancer Agent
A team led by Rice University synthetic organic chemist K.C. Nicolaou has developed a new process for the synthesis of a series of potent anti-cancer agents originally found in bacteria.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!